期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
Failure to disengage PI-3K pathway signaling confers Anti-IgM resistance to growth arrest and apoptosis in the CH12 B-cell lymphoma
1
作者 GREGORYBCAREY LAURATONNETTI DAVIDWSCOTT 《Cell Research》 SCIE CAS CSCD 2002年第3期283-283,共1页
We and others have firmly established that surface IgM receptor (sIgM-R) crosslinking with antibodies to the i heavy chain (anti-i) leads to growth arrest and apoptosis in a series of well characterized B-cell lymphom... We and others have firmly established that surface IgM receptor (sIgM-R) crosslinking with antibodies to the i heavy chain (anti-i) leads to growth arrest and apoptosis in a series of well characterized B-cell lymphomas. This requires ablation of c-Myc protein expression and the concomitant induction of the cyclin-dependent-kinase inhibitor, p27Kip1. The signaling mechanisms regulating c-Myc and p27Kip1 protein expression are poorly understood. However, we recently established that sIgM-R mediated down-modulation of the PI-3K pathway directly affected c-Myc and p27Kip1 expression and accurately predicted growth 展开更多
关键词 CH12B细胞淋巴瘤 细胞生长阻滞 细胞凋亡 PI-3K通路 信号转导 IgM受体抗体
下载PDF
Novel therapy for idiopathic pulmonary arterial hypertension: Can hepatocyte growth factor be beneficial?
2
作者 Ying-Hua Guo Long-Xiang SU +1 位作者 Na Guo Chang-Ting Liu 《Journal of Geriatric Cardiology》 SCIE CAS CSCD 2012年第2期211-212,共2页
Idiopathic pulmonary arterial hypertension (IPAH) is a progressive, nearly fatal condition that until recently has had very few treatment options. Median survival time for untreated IPAH was 2.8 years without effect... Idiopathic pulmonary arterial hypertension (IPAH) is a progressive, nearly fatal condition that until recently has had very few treatment options. Median survival time for untreated IPAH was 2.8 years without effective drug intervention. IPAH is characterized by deregulated proliferation of pulmonary arterial endothelial and intimal smooth muscle cells resulting in progressive pulmonary vascular remodeling and an increase in pulmonary arterial pressure. In order to alleviate their symptoms, anticoagulants, diuretics, calcium channel blockers and inotropic agents have been used to treat patients with PAH. Moreover, specific targeted therapies using prostacyclins, 展开更多
关键词 Idiopathic pulmonary arterial hypertension Hepatocyte growth factor TREATMENT MECHANISM
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部